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Abstract
Background: Challenging clinical practice guidelines that recommend serum potassium concentration between
4.0–5.0mEq/L or 4.5mEq/L in patients with acute myocardial infarction, recent studies found increased mortality
risks in patients with a serum potassium concentration of 4.5mEq/L. Studies investigating consequences of hypokalemia
after acute myocardial infarction revealed conflicting results. Therefore, the aim of this systematic review and meta-
analysis was to combine evidence from previous studies on the association of serum potassium concentration with both
short and long-term mortality as well as the occurrence of ventricular arrhythmias.
Design: Systematic review and meta-analysis.
Methods: A structured search of MEDLINE and EMBASE databases yielded 23 articles published between 1990 and
January 2017 that met the inclusion criteria. Study selection, data extraction and quality assessment were carried out by
three reviewers. Random effects models were used to pool estimates across the included studies and sensitivity analyses
were performed when possible.
Results: Twelve studies were included in the meta-analysis. Both pooled results from six studies investigating short-term
mortality and from five studies examining long-term mortality revealed significantly increased risks in patients with serum
potassium concentrations of <3.5mEq/L, 4.5–<5.0mEq/L and 5.0mEq/L after acute myocardial infarction. In addition, a
serum potassium concentration of <3.5mEq/L was significantly associated with the occurrence of ventricular
arrhythmias.
Conclusions: Mortality, both short and long term, and the occurrence of ventricular arrhythmias in patients with
acute myocardial infarction seem to be negatively associated with hypokalemic serum potassium concentration. There is
evidence for adverse consequences of serum potassium concentrations of 4.5mEq/L. Due to the heterogeneity among
existing studies, further research is necessary to confirm the need to change clinical practice guidelines.
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Introduction
Hypokalemia (serum potassium concentration
(SPC)< 3.5mEq/L) and hyperkalemia (SPC
5.0mEq/L) can have a variety of adverse consequences
in patients hospitalised after a cardiovascular event, for
instance higher mortality risks or ventricular arrhyth-
mia (VA).1–4 For patients with acute myocardial infarc-
tion (AMI), clinical practice guidelines recommend
SPCs of at least 4.0mEq/L,4 between 4.0 and
5.0mEq/L6,7 or above 4.5mEq/L.8 However, recent
studies in patients with AMI indicated that a SPC of
4.5mEq/L or greater was associated with increased
inhospital and 3-year mortality, respectively.9–11
Moreover, results from available studies investigating
the consequences of hypokalemia were conflicting.
Hypokalemia was found to be associated with
VA9,12–16 and higher mortality9,10,15 in some studies,
whereas others did not find increased risks for
VA10,17–19 or mortality11,16,19 in patients with AMI.
So far, although a number of studies are available, it
is difficult to reach an evidence-based conclusion
to suggest SPC might have adverse consequences in
AMI patients. Thus the objective of this study was to
provide a systematic review and meta-analysis of stu-
dies assessing the association of SPC with both
short and long-term mortality as well as VA in patients
with AMI.
Methods
The meta-analysis was conducted in accordance with
the preferred reporting items for systematic reviews
and meta-analyses (PRISMA) statement.20
Eligibility criteria
The study’s inclusion criteria were as follows: (a) sub-
jects with AMI; (b) assessment of SPC; (c) assessment
of mortality and/or VA; (d) humans.
Definition of endpoints
Short-term mortality includes assessments of all-cause
mortality within 6 months after AMI whereas long-
term mortality was defined as all-cause mortality later
than 6 months. VA was defined as abnormal rapid
heart rhythms that originate in the lower chambers of
the heart, such as ventricular tachycardia (VT) or ven-
tricular fibrillation (VF).
Data sources and search strategy
The MEDLINE and EMBASE databases (1990 to
25 January 2017) were searched for studies that exam-
ined the association of SPC with mortality and/or VA
in patients with AMI using the following MeSH
headings/text words: potassium/blood; hypokalemia;
hyperkalemia; mortality; arrhythmia, cardiac; tachy-
cardia, ventricular; fibrillation, ventricular. The
detailed strategy is shown in Supplementary Tables 1
and 2. No language restrictions were applied.
Electronic searches were supplemented with a review
of the reference lists of retrieved articles.
Study selection
The screening of titles and abstracts for eligibility was
carried out by two authors independently (MGC and
LD, MGC and IK, MGC and UA). Disagreements
were solved by discussion or by reading the full text
article. The full texts were also read independently by
two authors (MGC and IK, MGC and UA).
Disagreements were solved by discussion. The decision
as to which studies to include in the meta-analysis was
based on the quality assessment and on the SPC cat-
egory used as reference to ensure comparability of effect
sizes across studies. Studies scoring higher than five in
the quality assessment were included.
Data extraction
Two authors each (MGC and IK, MGC and
UA) extracted and collected data independently.
Disagreements were resolved by discussion. The follow-
ing data were abstracted: publication information
(authors, title, journal, publication year); study charac-
teristics (design, objectives, data source, data collection
period, inclusion/exclusion criteria); patient character-
istics (sample size, age, sex, event rates (short and long-
term mortality and VA); methods (AMI definition, SPC
measurement and classification, statistical methods,
confounders); and reported outcomes (definition,
assessment, effect sizes). Studies reported SPC in milli-
equvalents per litre (mEq/L) or millimoles per liter
(mmol/L). Both units can be used interchangeably in
this case, but for the sake of simplicitymEq/L will be
used throughout this article.
Quality assessment
Quality assessment was performed using a selection of
12 items from the checklist for measuring study qual-
ity,21 which are appropriate to assess the quality of
observational studies. This checklist was complemented
by two items from the Cochrane Collaboration’s tool
for assessing risk of bias22 (‘Were incomplete outcome
data adequately assessed?’ and ‘Was the study appar-
ently free of other problems that could put it at risk of
bias?’) as well as three self-developed criteria
(‘Were withdrawals/drop-outs reported?’, ‘Were data
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collection methods clearly described?’ and ‘Were
appropriate categories chosen to classify SPC?’). Each
of the 17 items was scored ‘1’ (yes) or ‘0’ (no or unable
to determine) and a summary score was built ranging
from 0 (lowest quality) to 17 (highest quality).
Quality assessments were each performed by two
authors (MGC and IK, MGC and UA) independently.
Disagreements were resolved by discussion.
Meta-analysis
Meta-analysis was performed using the comprehensive
meta-analysis software version 3.0.23 In a conservative
approach, the random effects model which allows for
variation of true effects across studies was chosen.
Heterogeneity was assessed by the I2 statistics. As the
number of included studies was less than 10 for each of
the three endpoints, we refrained from any tests on
publication bias, which may have too low a power to
distinguish chance from reality.24
Results
The literature search revealed 2285 publications (see
Figure 1). We identified 23 articles fulfilling our inclu-
sion criteria (see Table 1). Apart from one study,15 all
of them were observational studies. Five papers inves-
tigated the association between SPC and all three out-
comes (short, long-term mortality and VA). The
summary quality scores assessed for each paper are
provided in Table 1. Overall, only three studies did
not reach a quality score higher than five.25–27
Adjustment for relevant confounders was a crucial
determinant during quality assessment.
Supplementary Table 3 provides an overview of the
confounders considered in each of the included studies.
Short-term mortality
The literature search yielded 12 studies which investi-
gated the association between SPC and short-term mor-
tality (see Table 2). In three out of six studies that
Records identified through database
searching (EMBASE, MEDLINE)
(n = 2285)
Additional records identified
through other sources
(n = 0)
Records after duplicates removed
(n = 1878)
Records screened
(n = 1878)
Full-text articles assessed
for eligibility
(n = 123)
Studies included in
qualitative synthesis
(n = 23)
Studies included in
quantitative synthesis
(meta-analysis)
(n = 7)
Records excluded
(n = 1755)
Full-text articles (n = 100)
excluded, that did not
include subjects with AMI,
had no assessment of serum
potassium concentration
or no assessment of
mortality and/or ventricular
arrhythmia
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Figure 1. Flow diagram.
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provided a detailed classification of SPCs, patients with
SPC between 3.5 and less than 4.0mEq/L showed the
lowest, unadjusted short-term mortality risk.9,15,16 In
the study by Choi et al.10 and Ma et al.19 patients
with a SPC of 3.5 to less than 4.0mEq/L and patients
with a SPC of 4.0 to less than 4.5mEq/L had a similar
risk of dying. In contrast, Keskin et al.28 found a
slightly higher inhospital mortality (3.7%) in patients
with a SPC of 3.5 to less than 4.0mEq/L than
in patients with a SPC of 4.0 to less than
4.5mEq/L (3.1%).
Six studies were included in the meta-analysis. The
SPC category of 3.5 to less than 4.0mEq/L served as
the reference category. Goyal et al.9 and Keskin et al.28
provided more than five SPC categories. In order to fit
the required number of categories, both the highest and
lowest categories were combined with the next lower or
next higher category, respectively. In two studies,
adjusted odds ratios (ORs) were used as effect
sizes,9,16 whereas Ma et al.19 and Patel et al.15 provided
hazard ratios (HRs). Choi et al.10 reported an unad-
justed number of events and Keskin et al.28 used a dif-
ferent reference category than required. In order to
include all studies in the meta-analysis, the unadjusted
number of deaths from the studies of Keskin et al.,28
Ma et al.19 and Patel et al.15 was used in the analysis.
Four of the included studies investigated inhospital
mortality. From Ma et al.19 the data on 7-day mortality
were included, and from Patel et al.15 data on 14-day
mortality were included.
The meta-analysis showed pooled ORs for all SPC
categories in a U-shaped manner (see Figure 2). Except
for the SPC category of 4.0 to less than 4.5mEq/L, all
estimates were significant. There was no indication
for heterogeneity in the analyses of the SPC categories
of less than 3.5mEq/L (I2¼ 0), but substantial
heterogeneity in the analyses of the SPC categories of
4.0 to less than 4.5mEq/L (I2¼ 55.6), 4.5 to less
than 5.0mEq/L (I2¼ 74.3) and 5.0mEq/L or greater
(I2¼ 89.7).
As a sensitivity analysis, the studies which were
responsible for most of the heterogeneity were excluded
and the pooled effect sizes were re-estimated. In the
SPC category of 4.0 to less than <4.5mEq/L, the exclu-
sion of Keskin et al.28 led to an increase of the pooled
OR from 1.06 to 1.17 (95% confidence interval (CI)
1.03–1.33), which was significant in contrast to the pre-
vious analysis with all six studies. Exclusion of
Uluganyan et al.16 in the SPC category of 4.5 to less
than 5.0mEq/L resulted in an increase of the pooled
effect size from OR 1.53 to 1.60 (95% CI 1.12–2.27). In
the SPC category of 5.0mEq/L or greater the exclusion
of Choi et al.10 led to a reduction of the pooled effect
size from OR 3.85 to 2.54 (95% CI 1.64–3.95), which
still remained significant.T
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Long-term mortality
Seven studies were identified investigating the associ-
ation of SPC and long-term mortality (see Table 3).
In three out of six studies reporting crude mortality
rates per SPC category, patients with SPC between 3.5
and less than 4.0mEq/L showed the lowest, unadjusted
long-term mortality risk.15,16,30 Studies which used a five-
level SPC classification with values of 3.5 to less than
4.0mEq/L as the reference category found a U-shaped
association with higher mortality risks for SPC below
3.5mEq/L, and equal to or above 4.0mEq/L with a
trend for increased risk estimates with increasing
SPC10,15,16 (see Table 3). Shiyovich et al.11 and Keskin
et al.28 classified SPC into seven categories with values of
4.0 to 4.5 or less as the reference category. Shiyovich
et al.11 showed that a SPC above 4.5mEq/L was signifi-
cantly associated with higher mortality at 6 months,
1 year and 5 years. Keskin et al.28 found that SPCs
less than 3.5mEq/L as well as SPCs greater than
5.0mEq/L were associated with a higher 4-year mortality
risk compared with the reference concentration.
As the seven studies used different effect estimates
(OR and HR) and different reference categories it was
not possible to perform a meta-analysis on the results
from the adjusted regression models. Nonetheless, it
was possible to include unadjusted ORs with values
of 3.5 to less than 4.0mEq/L as the reference category
from four studies10,11,15,28 and adjusted ORs from
Uluganyan et al.16 in the meta-analysis. From the
study of Shiyovich et al.,11 the data on 1-year mortality
were used. Significantly higher pooled ORs (1.75, 95%
CI 1.28–2.40) were found for SPCs of less than
3.5mEq/L, for 4.5 to less than 5.0mEq/L (OR 1.60,
95% CI 1.16–2.19) and for greater than 5.0mEq/L
(OR 3.29, 95% CI 2.10–5.15) (see Figure 3).
Moderate heterogeneity was found in the models for
SPC of less than 3.5mEq/L (I2¼ 46%) and for concen-
trations of 4.0 to less than <4.5mEq/L (I2¼ 48%). The
pooled models on SPC of 4.5 to less than 5.0mEq/L
and greater than 5.0mEq/L indicated substantial het-
erogeneity (I2¼ 68% and 75%, respectively).
Sensitivity analyses showed that replacing data on 1-
year mortality from Shiyovich et al.11 with data on 6-
month mortality from the same study yielded compar-
able results. The inclusion of unadjusted data instead of
adjusted data from Uluganyan et al.16 resulted in
slightly higher effect estimates.
Ventricular arrhythmia
The literature search yielded 18 studies which investi-
gated the association between SPC and VA (see
Table 4).
A number of studies dichotomised SPC and com-
pared VA rates in SPC groups of less than 3.5,13,32,37
less than 3.612 or less than 4.0mEq/L34 with higher
Study name
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Figure 2. Pooled odds ratios (random effects) of admission serum potassium concentration associated with short-term mortality in
patients with acute myocardial infarction.
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concentrations. Madias et al.13 found a significantly
higher number of VFs in the group of less than
3.5mEq/L but not a significantly higher occurrence of
VT compared with higher SPC. Su et al.32 and Higham
et al.37 both found a higher number of malignant
arrhythmia and VF in patients with SPCs of less than
3.5mEq/L, and Fiol Sala et al.12 and Maciejewski
et al.34 confirmed these findings for VF and for VF,
VT and atrial fibrillation, with slightly different SPC
categories of less than 3.6 and less than 4.0mEq/L,
respectively. Except for Higham et al.,37 all studies
used single admission SPC. Some other studies used a
SPC classification that did not match the common
categorisation.17,30,36
Among the six studies that used a classification of
SPC in five or seven categories, four studies reported
the highest rates of VA in patients with SPCs less than
3.0mEq/L9,28 or less than 3.5mEq/L.15,16 In contrast,
in the studies from Choi et al.10 and Ma et al.,19
patients with SPCs of 5.0mEq/L or greater had the
highest rates of VA occurrence. Multivariable regres-
sion analyses revealed a significantly increased VA risk
for patients with SPCs less than 3.5mEq/L in the study
by Keskin et al.,28 whereas Ma et al.,19 Uluganyan
et al.16 and Choi et al.10 found no significantly
increased risk. Goyal et al.9 showed a higher odds for
SPC of less than 3.5mEq/L only when single admission
SPC was used for the analysis, but not when mean SPC
was analysed.
Six studies were included in the meta-analy-
sis.9,10,15,16,19,28 The SPC category of 3.5 to 4.0mEq/L
or less was used as the reference category. Goyal et al.9
and Keskin et al.28 provided more than five SPC cate-
gories. In order to fit the required number of categories,
both the highest and lowest categories were combined
with the next lower or next higher category, respect-
ively. In two studies,9,16 adjusted ORs were used as
effect sizes, whereas Ma et al.19 provided adjusted
HRs and Patel et al.15 and Choi et al.10 reported unad-
justed numbers of events. Keskin et al.28 used a differ-
ent reference category. In order to include all studies in
the meta-analysis, the unadjusted number of deaths
from the studies of Ma et al.19 and Keskin et al.28
was used in the analysis.
For SPCs of less than 3.5mEq/L a significantly
higher pooled OR (1.61, 95% CI 1.31–1.97) was
found compared with SPCs of 3.5 to less than
4.0mEq/L and significantly lower ORs were detected
for SPCs of 4.0 to less than 4.5mEq/L and greater
than 5.0mEq/L (see Figure 4).
No heterogeneity (I2¼ 0%) was found in two of the
models. The pooled models on SPCs of 4.5 to less than
5.0mEq/L and greater than 5.0mEq/L indicated sub-
stantial heterogeneity (I2¼ 55% and I2¼ 70%, respect-
ively). As the observed heterogeneity may be associated
with the differences regarding SPC measurement, sep-
arate analyses were run for studies using admission
SPCs9,15,16 or mean SPCs.9,10,19,28 Within SPCs of less
Study name Odds ratio and 95% CI Odds ratio and 95% CIStatistics for each study Statistics for each study
<3.5 mEq/l 4.0–<4.5 mEq/l
Long-term mortality
0.01 0.1 1 10 100
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Figure 3. Pooled odds ratios (random effects) of long-term mortality associated with serum potassium concentration relative to
category of 3.5<4.0mEq/l.
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than 3.5mEq/L in both subgroups a significantly
increased pooled risk was found compared with the
reference SPC. In contrast, the pooled OR among
SPCs of less than 4.0 to less than 4.5mEq/L was
lower and significant in the studies with an admission
SPC measurement (OR 0.84, 95% CI 0.75–0.95) com-
pared with the pooled OR in the studies with a mean
SPC measurement (OR 0.93, 95% CI 0.81–1.08). In the
SPC group 4.5 to 5.0mEq/L the results were completely
different, with a lower pooled OR of 0.80 (95% CI
0.69–0.92) among studies with an admission SPC meas-
urement and a higher pooled OR of 1.15 (95% CI 0.99–
1.33) found among studies with a mean SPC measure-
ment. A significant difference between the subgroups
was found for SPCs of 5.0mEq/L or greater with a
significantly decreased pooled OR of 0.72 (95% CI
0.60–0.85) in studies with an admission SPC measure-
ment in contrast to a significantly increased pooled OR
of 1.61 (95% CI 1.23–2.09) in studies with a mean SPC
measurement. No indication of heterogeneity
(I2< 34%) was found in the analyses above.
Discussion
This systematic review and meta-analysis showed that
SPCs less than 3.5mEq/L and 4.5mEq/L or greater in
patients with AMI were associated with a higher risk of
short-term mortality compared with SPCs of 3.5 to less
than 4.0mEq/L. Likewise, a U-shaped association of
SPC and long mortality was found, with the exception
that patients with SPCs of 4.0 to less than 4.5mEq/L
had a similar risk to patients with SPCs of 3.5 to less
than 4.0mEq/L. In addition, SPCs less than 3.5mEq/L
were associated with an increased risk of VA.
A most interesting result is the finding that the asso-
ciation between SPC and outcomes seems to be
U-shaped and that recommendations simply to increase
SPC in AMI patients may therefore be misleading. Our
meta-analysis indicates that SPCs of 4.5mEq/L and
beyond negatively affect post-AMI survival. This find-
ing may be at least partly explained by the association
of hyperkalemia with reduced ventricular excitability
that can result in complete heart block and sinus
arrest.38,39 Higher SPCs may also indicate renal failure,
which constitutes a major risk factor for post-AMI sur-
vival.40 However, most of the studies included in the
meta-analysis have considered renal function as a con-
founder and SPCs of 5mEq/L or greater remained sig-
nificantly associated with higher mortality rates after
adjustment.9,10,15,28
Overall, the present systematic review and meta-ana-
lysis confirmed that SPC of less than 3.5mEq/L was
negatively associated with survival and VA after
AMI. This is well known among the medical commu-
nity and part of all AMI treatment guidelines.5–8T
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However, the present analysis also confirmed this find-
ing in more recent studies conducted in the ‘reperfusion
era’, in which standard AMI treatment includes early
invasive treatment and routine use of beta-blockers.
Beta-blockers raise SPC by blocking epinephrine-
induced depression of SPC through beta-receptor
stimulation.41,42 A considerable number of studies on
the association between SPC and VA were performed
before the reperfusion era12,17,27,35–37 or analysed data
were collected before the year 1990.13 However, the
management of both ST-segment elevation myocardial
infarction (STEMI) and non-STEMI has advanced
substantially over the past 20 years. The application
of beta-blockers in acute coronary syndrome (ACS),
reperfusion and antiplatelet treatment has decreased
the risk of VF in ACS by at least one third.43,44
Practice guidelines, including recommendations on
SPC in the management of AMI, are based on these
older studies that might not apply to contemporarily-
treated AMI patients. Almost all of these early studies
have investigated the association of hypo and hyperka-
lemia and VA using a dichotomous classification of
SPC. In our meta-analysis we aimed to investigate the
effects of a more finely graduated SPC classification,
and therefore we excluded earlier studies. The analysis
of this more detailed SPC classification yielded
interesting results. Our meta-analysis confirmed the
well-described association of SPC of less than
3.5mEq/L and the occurrence of VA, but also yielded
conflicting results in terms of higher SPC depending on
the type of SPC collection. While the pooled risk of VA
in patients with SPC of 4.5 to less than 5.0mEq/L and
5.0mEq/L or greater was decreased in studies using
single admission SPC,9,15,16 it was significantly
increased in studies using a mean value of several
SPC measurements during hospitalisation.9,10,19,28
Goyal et al.9 have already observed a similar effect in
their study in which they reported results for admission
SPC as well as mean SPC. According to American
College of Cardiology/American Heart Association
STEMI guidelines, aggressively normalising SPC to
greater than 4.0mEq/L in post-AMI patients with VA
is recommended.7 When extracellular SPC falls below
3.5mEq/L, the risk of VT and VF is increased in
patients with AMI due to a number of electrophysio-
logical changes.45 Efforts to normalise SPC in hypokal-
emic patients combined with medical and drug
treatment affecting potassium homeostasis might
cause the SPC subsequently to exceed 4.5mEq/l.46,47
Thus hyperkalemia following hypokalemia could
explain why studies using the mean SPC found signifi-
cantly increased risks of VA in patients with SPC of 4.5
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Figure 4. Pooled odds ratios (random effects) of ventricular arrhythmia associated with serum potassium concentration relative to
category of 3.5<4.0mEq/l.
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to less than 5.0mEq/l and 5.0mEq/L or greater, while
those using the admission SPC did not. In addition,
apart from the information that VA occurred during
hospital stay, studies did not report the exact time of
VA onset. The mean SPC might contain SPC measure-
ments that were taken before as well as after the onset
of VA. Thus this would not allow reliable conclusions
to be drawn on the relationship of mean SPC and VA.
To conclude, using the mean SPC might overestimate
the risk of VA in patients with SPC of 4.5 to less than
5.0mEq/L and 5.0mEq/L or greater.
The present systematic review and meta-analysis
provided an overview on available scientific evidence
regarding SPC and AMI outcomes. A strength of this
paper is the inclusion of results of recent and high-qual-
ity studies from the reperfusion era, which were not
considered in the available practice guidelines for
AMI treatment so far. The meta-analysis enabled an
increase of statistical power in the extremes of SPC
that were often characterised by small numbers of
events in the single studies.
However, several limitations should be considered.
The studies combined in the meta-analyses on the dif-
ferent outcomes have slightly different study character-
istics e.g. in terms of AMI type, follow-up period, time
and frequency of SPC assessment. Due to the small
number of retrieved studies it was not always possible
to perform sensitivity analyses to estimate the effects of
these heterogeneous characteristics on the pooled effect
sizes. Moreover, it was not possible to include the con-
founder-adjusted estimates from all studies in the meta-
analyses, because studies used HRs as effect sizes
instead of ORs or different reference categories. The
inclusion of the unadjusted results may have led to an
overestimation of the pooled effects. Thus the pooled
effects should be interpreted with caution. We have
assessed the quality of the studies using a summary
score with unweighted items, which may be difficult
to interpret and the definition of the threshold for
exclusion may be arbitrary.
The results of this systematic review and meta-ana-
lysis support the guideline recommendation that SPC
should not be lower than 3.5mEq/L in patients with
AMI in order to improve short and long-term survival
and to avoid VA. However, guideline recommendations
that SPC should be at least 4.5mEq/L or higher in
AMI patients are challenged by the scientific evidence
from the studies included in this systematic review and
meta-analysis. The results indicate that higher SPC
concentrations may be adversely associated with short
and long-term survival. The reservation must be made,
however, that due to the high heterogeneity among
existing studies and the limitations mentioned above,
further research is necessary to confirm the need to
change clinical practice guidelines.
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